Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's gapping premarket!!! Expect .02+ today
Doubt it. People would buy the dip and push the price back up
I highly doubt it. There are too many eyes on this.
It looks like we have a lot of long-term investors on this and not just flippers. This means there will be relatively few people selling which will shoot the price up! Hold on tight!
GLTA
That means he's not sure..
How can I see his picks?
Gold is dropping. I'm out. GLTA
New HOD!!! This is going to .003!!
I have a good feeling we'll see that
The price of gold is increasing!
30 million on the ask? That's insane. This looks like it's being shorted or diluted.
Does anyone know what the volume was yesterday?
In talking about this year...not 52 weeks in the past.
I have complained to iHub and so have other users. We're just waiting to hear back from them.
Huge buys coming in!
Yes. He mentioned in an email that PR will be released regularly from now on due to lies being spread about the stock.
Agreed. He has extensive experience and seems well qualified. Dr. O wouldn't shell out money for someone like that unless he has big plans for the company.
https://www.linkedin.com/in/ivanklarich
Link to the LinkedIn profile of the newly hired expert..you can see he has a lot of experience in business and strategic planning. I'm excited to see what he brings to the table.
This shows that Dr. O is serious about putting this drug out there and getting it to where it's needed. Great things to come.
NEWS FOR VDRM!! HIRES EXPERIENCED PRODUCT EXPERT
ViaDerma, Inc. (VDRM: OTC Pink Current) | ViaDerma, Inc. Hires Product Rollout Expert to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch
The Company Plans to Expand the Personnel Infrastructure to Handle the Critical Go to Market Demands of Launching New Products here in the USA and Abroad for its FDA registered Viabecline topical antibiotic product that uses the Proprietary Patent Pending Delivery System
LOS ANGELES, CA–(Marketwired – March 08, 2017) – ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has hired Mr. Ivan Klarich, who is an expert in managing the launching of „Go to Market” strategies for new product compliance. The Company wants to avoid the pitfalls often found in the launching a new product or product line. The Company wants to assure a solid strategy behind the launch for the labeling, marketing and distribution. The „Quality Control” plan will assure the product meets strict guidelines, starting with the manufacturer all the way through to the point of purchase. The Company plans to continue to hire several experts in the specialty pharmaceutical field as the Company rolls out an aggressive growth plan for 2017 and the years ahead.
Mr. Klarich brings over 20 years of experience in the area of go-to-market strategy and product rollout. He has experience in working with FDA compliant manufacturers and the registration process required to sell OTC products internationally.
The Company’s President, Dr. Christopher Otiko has been Selected to write an article in a leading Diabetic publication, the „Journal of Diabetes Science and Technology.” Dr. Otiko has also been invited to present his abstract work at DFCON or the Diabetic Foot Global Conference in Houston, TX, March 23rd through the 25th. DFCon, website www.dfcon.com/, is the premier international, interdisciplinary diabetic foot conference in North America. Viabecline is more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not,” said CEO Dr. Christopher Otiko. „Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are „forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as „anticipate,” „believe,” „expect,” „future,” „may,” „will,” „would,” „should,” „plan,” „projected,” „intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company’s future operating results are dependent upon many factors, including but not limited to the Company’s ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company’s control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
Copyright © 2017 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
It looks like .04 is resistance. Once we break through that this should fly!
Because people know how undervalued we are and there's PR coming out soon.
An email from Dr. O. A screenshot was posted earlier.
Almost at .04!!
Sorry but bashing this stock won't hold it down.
New high of the day. This thing may be reversing.
L2 looks great!
PR coming out very soon!
Level 2 looks great! This seems to be reversing.
Nice! That means tomorrow will be a great day for this stock.
You mean 300,000
Thanks for that detailed explanation. It sounds to me like this Kenough guy got greedy and wanted the entire cake for himself. It makes sense that the previous patents filed have been abandoned due to him not being the rightful owner of the patents. I believe that Dr. Otiko is doing what he says and is working on something big...he has a reputation to uphold and wouldn't risk it all by lying in news releases. I'm confident all of the pieces will eventually come together. Have a good night.
Who is this Keough guy? I thought Otiko is the CEO?
When did that happen?
We had pretty good closing and L2 looks good with huge bids. I think we'll get the volume we need on Monday and this will go flying.
The spread is huge! If the asks win we fly over .05. If the bids win this will drop.
Daily chart looks good. Based on past runs this should hit .07 by tomorrow and test .1 by Friday. GLTA
TA shows that this is the start of the next leg up..we should reach .10+ in a few days.
We need more volume
This is our FOURTH green day in a row! I expect us to see .15 cents tomorrow
I have a good feeling we will before the end of this week. We've had 4 consecutive green days on quite low volume.